Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer

Table 1 Baseline characteristics

	Group with TA (n: 15)	Group without TA (n: 15)
Median age, years (range)	83.0 (80.2-89.6)	81.3 (80.0-89.3)
Sex, %
Male	5 (33.3)	10 (66.7)
Female	10 (66.7)	5 (33.3)
Comorbidity, %1
Hypertension	8 (57.1)	9 (64.3)
Diabetes mellitus	4 (28.6)	2 (14.3)
Cardiac valve disease	5 (35.7)	2 (14.3)
Pulmonary embolism	1 (7.1)	4 (28.6)
Ischemic heart disease	1 (7.1)	3 (21.4)
Primary location of tumor, %
Right colon	9 (64.3)	10 (71.4)
Transverse colon	2 (14.3)	4 (28.6)
Left colon	1 (7.1)	0
Rectum	1 (7.1)	0
Metastatic site, %1
Liver	8 (53.3)	10 (66.7)
Peritoneum	6 (40.0)	5 (33.3)
Lung	5 (33.3)	5 (33.3)
Distant LN	4 (26.7)	2 (12.5)
Bone	4 (26.7)	2 (12.5)
Others	1 (6.7)	1 (6.7)
Surgery
Curative	8 (53.3)	6 (40.0)
Palliative	3 (20.0)	2 (13.3)
None	4 (26.7)	7 (46.7)
No. of metastases
1	5 (33.3%)	10 (66.7%)
2	8 (53.3%)	2 (13.3%)
≥ 3	2 (13.3%)	3 (20.0%)
Adjuvant chemotherapy
Yes	5 (62.5)	2 (33.3)
No	3 (37.5)	4 (66.7)
1st line chemotherapy regimen
FOLFOX	9 (60.0)	15 (100)
FOLFIRI	6 (40.0)	0

¹The number of metastatic sites exceeds that of subjects, due to patients with multiple metastases. TA: Targeted agent; LN: Lymph node; FOLFOX: Fluoruracil, leucovorin and oxaliplatin; FOLFIRI: Fluoruracil, leucovorin and irinotecan.